This summary was created by AI, based on 3 opinions in the last 12 months.
Experts are positive about Boston Scientific Corp's strong revenue beat and raise in full-year forecast, as well as its consistent gains. They suggest it's worth buying despite a slight sell-off. Comparatively, they advise against TMO due to flattening revenues and high PE, instead favoring BDX or Boston Scientific for better performance.
Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.
Still owns shares. Venture capital fund in health care business. One of most successful funds in biotech. Expecting consistent gains going forward.
Above FMV of $40 by 22%. Growth is fairly nice. He thinks it will hold fairly well. A bouncy kind of stock.
It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.
It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.
Boston Scientific Corp is a American stock, trading under the symbol BSX-N on the New York Stock Exchange (BSX). It is usually referred to as NYSE:BSX or BSX-N
In the last year, 3 stock analysts published opinions about BSX-N. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Boston Scientific Corp.
Boston Scientific Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Boston Scientific Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Boston Scientific Corp In the last year. It is a trending stock that is worth watching.
On 2024-12-06, Boston Scientific Corp (BSX-N) stock closed at a price of $90.07.
It just reported a strong revenue beat with over 14.7% organic growth and raise their full-year forecast in earnings and revenues. Was down 1% today in the sell-off, but still worth buying.